X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25377) 25377
Book Review (3312) 3312
Publication (1651) 1651
Newsletter (422) 422
Conference Proceeding (57) 57
Newspaper Article (49) 49
Book Chapter (44) 44
Dissertation (30) 30
Magazine Article (16) 16
Book / eBook (5) 5
Government Document (5) 5
Transcript (4) 4
Trade Publication Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22012) 22012
humans (19980) 19980
paclitaxel (14653) 14653
female (14218) 14218
paclitaxel - administration & dosage (12142) 12142
oncology (11673) 11673
middle aged (9774) 9774
chemotherapy (8666) 8666
aged (8651) 8651
antineoplastic combined chemotherapy protocols - therapeutic use (7983) 7983
male (7798) 7798
cancer (7380) 7380
adult (6933) 6933
treatment outcome (5466) 5466
animals (5043) 5043
pharmacology & pharmacy (4131) 4131
breast neoplasms - drug therapy (3557) 3557
cisplatin (3511) 3511
carboplatin - administration & dosage (3264) 3264
antineoplastic combined chemotherapy protocols - adverse effects (3261) 3261
paclitaxel - adverse effects (3072) 3072
mice (2955) 2955
lung neoplasms - drug therapy (2935) 2935
antineoplastic agents, phytogenic - administration & dosage (2933) 2933
care and treatment (2927) 2927
drug administration schedule (2918) 2918
cisplatin - administration & dosage (2899) 2899
paclitaxel - therapeutic use (2780) 2780
cell line, tumor (2753) 2753
ovarian neoplasms - drug therapy (2723) 2723
carboplatin (2714) 2714
therapy (2685) 2685
breast cancer (2678) 2678
docetaxel (2630) 2630
neoplasm staging (2611) 2611
trial (2464) 2464
carcinoma (2447) 2447
research (2408) 2408
aged, 80 and over (2328) 2328
disease-free survival (2304) 2304
carcinoma, non-small-cell lung - drug therapy (2279) 2279
drug delivery systems (2260) 2260
nanoparticles (2244) 2244
taxol (2212) 2212
paclitaxel - pharmacology (2185) 2185
analysis (2128) 2128
antineoplastic agents - administration & dosage (2120) 2120
ovarian cancer (2110) 2110
breast neoplasms - pathology (2045) 2045
antineoplastic combined chemotherapy protocols - administration & dosage (2040) 2040
doxorubicin (1999) 1999
antineoplastic agents (1991) 1991
tumors (1883) 1883
antimitotic agents (1873) 1873
drug therapy (1862) 1862
dose-response relationship, drug (1861) 1861
medicine & public health (1826) 1826
deoxycytidine - analogs & derivatives (1806) 1806
survival rate (1805) 1805
drugs (1800) 1800
survival (1800) 1800
antineoplastic agents - therapeutic use (1713) 1713
retrospective studies (1669) 1669
survival analysis (1653) 1653
combined modality therapy (1647) 1647
prognosis (1617) 1617
time factors (1594) 1594
metastasis (1593) 1593
deoxycytidine - administration & dosage (1565) 1565
combination (1542) 1542
obstetrics & gynecology (1532) 1532
gemcitabine (1530) 1530
antineoplastic agents, phytogenic - therapeutic use (1503) 1503
lung neoplasms - pathology (1493) 1493
apoptosis (1486) 1486
health aspects (1456) 1456
taxoids - administration & dosage (1430) 1430
follow-up studies (1429) 1429
in-vitro (1425) 1425
hematology, oncology and palliative medicine (1398) 1398
clinical trials (1368) 1368
doxorubicin - administration & dosage (1360) 1360
ovarian neoplasms - pathology (1352) 1352
breast-cancer (1342) 1342
paclitaxel - pharmacokinetics (1327) 1327
paclitaxel - analogs & derivatives (1316) 1316
cardiac & cardiovascular systems (1314) 1314
abridged index medicus (1306) 1306
neoplasms - drug therapy (1301) 1301
cancer therapies (1300) 1300
pharmacokinetics (1293) 1293
taxoids (1281) 1281
phase-ii trial (1244) 1244
surgery (1244) 1244
toxicity (1237) 1237
dosage and administration (1232) 1232
chemotherapy, adjuvant (1229) 1229
phase-ii (1228) 1228
bevacizumab (1207) 1207
prospective studies (1190) 1190
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24529) 24529
Japanese (768) 768
Chinese (201) 201
French (152) 152
German (86) 86
Russian (38) 38
Spanish (35) 35
Italian (32) 32
Korean (19) 19
Hungarian (17) 17
Polish (13) 13
Czech (8) 8
Dutch (6) 6
Danish (4) 4
Portuguese (4) 4
Turkish (3) 3
Hebrew (2) 2
Lithuanian (2) 2
Croatian (1) 1
Finnish (1) 1
Romanian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3639 - 3648
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 06/2012, Volume 81, Issue 2, pp. 248 - 256
Schematic illustration of drug-loaded folic acid targeted nanoparticles of mixed lipid-shell and PLGA core (FLPNPs). A functional drug carrier comprised of... 
Drug delivery | PLGA | Nanoparticle | Paclitaxel | GYNECOLOGIC-ONCOLOGY-GROUP | BIODEGRADABLE MICROSPHERES | DRUG-DELIVERY | CONTROLLED-RELEASE | PHASE-II | LIPOSOMAL DAUNORUBICIN | CANCER | RECURRENT | ENDOTHELIAL-CELLS | METASTATIC NASOPHARYNGEAL CARCINOMA | PHARMACOLOGY & PHARMACY | Polymers - administration & dosage | Nanoparticles - chemistry | Humans | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Drug Carriers - chemistry | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Lipids - chemistry | Female | Paclitaxel - administration & dosage | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Lactic Acid - chemistry | Drug Compounding - methods | Chitosan - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Lipids - administration & dosage | Mice, SCID | Chemistry, Pharmaceutical | Polyethylene Glycols - administration & dosage | Particle Size | Animals | Chitosan - chemistry | Polyglycolic Acid - chemistry | Cell Line, Tumor | Folic Acid - metabolism | Polymers - chemistry | Mice | Nanoparticles - administration & dosage | HeLa Cells | Drug Delivery Systems - methods | Drugs | Phosphates | Drug delivery systems | Leukemia | Liquid chromatography | Permeability | Chromatography | Folic acid | Vehicles | Nanoparticles | Lysine | Fluorescein | Dimethyl sulfoxide | Lymphomas | Index Medicus
Journal Article
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | Index Medicus | Abridged Index Medicus | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3347 - 3353
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents |